Patents by Inventor Stefan Loverix
Stefan Loverix has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210155699Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.Type: ApplicationFiled: November 16, 2020Publication date: May 27, 2021Applicant: Genmab A/SInventors: Aran Frank LABRIJN, Stefan LOVERIX, Paul PARREN, Jan VAN DE WINKEL, Janine SCHUURMAN, Ignace LASTERS
-
Publication number: 20180319888Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.Type: ApplicationFiled: May 11, 2018Publication date: November 8, 2018Inventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jan Van De Winkel, Janine Schuurman, Ignace Lasters
-
Patent number: 10023647Abstract: Provided herein are polypeptides that are capable of crossing the cellular membrane and entering into the intracellular environment, which polypeptides are suitable for use in prophylactic, therapeutic or diagnostic applications as well as in screening and detection. Nucleic acids encoding such polypeptides; methods for preparing such polypeptides, host cells expressing or capable of expressing such polypeptides, compositions, and in particular pharmaceutical compositions, that comprise such polypeptides, in particular for prophylactic, therapeutic or diagnostic purposes are also provided.Type: GrantFiled: October 22, 2013Date of Patent: July 17, 2018Assignee: COMPLIX NVInventors: Stefan Loverix, Philippe Alard, Sabrina Deroo, Klaartje Somers, Ignace Lasters, Johan Desmet
-
Patent number: 10000570Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.Type: GrantFiled: June 15, 2015Date of Patent: June 19, 2018Assignee: Genmab A/SInventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jan Van De Winkel, Janine Schuurman, Ignace Lasters
-
Patent number: 9969778Abstract: The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein on or more amino acids in the HA2 domain have been mutated. Also provided are nucleic acids encoding the polypeptides, compositions comprising the polypeptides and/or nucleic acid molecules, as well as methods of their use, in particular in the detection, prevention and/or treatment of influenza.Type: GrantFiled: August 31, 2016Date of Patent: May 15, 2018Assignee: JANSSEN VACCINES & PREVENTION B.V.Inventors: Jan Willem Meijberg, Antonietta Impagliazzo, Ronald Vogels, Robert H. E. Friesen, Philippe Alard, Stefan Loverix, Katarina Radosevic
-
Patent number: 9701717Abstract: The application provides Alphabodies that specifically bind to IL-23, as well as to polypeptides that comprise or essentially consist of such Alphabodies. Also provided herein are nucleic acids encoding such Alphabodies; to methods for preparing such Alphabodies and polypeptides; and in particular to pharmaceutical compositions, that comprise such Alphabodies, polypeptides, nucleic acids and/or host cells.Type: GrantFiled: October 22, 2013Date of Patent: July 11, 2017Assignee: COMPLIX NVInventors: Johan Desmet, Maria Paulina Henderikx, Klaartje Somers, Stefan Loverix, Mark Vaeck, Ignace Lasters
-
Publication number: 20160362455Abstract: The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein on or more amino acids in the HA2 domain have been mutated. Also provided are nucleic acids encoding the polypeptides, compositions comprising the polypeptides and/or nucleic acid molecules, as well as methods of their use, in particular in the detection, prevention and/or treatment of influenza.Type: ApplicationFiled: August 31, 2016Publication date: December 15, 2016Applicant: Janssen Vaccines & Prevention B.V.Inventors: Jan Willem Meijberg, Antonietta Impagliazzo, Ronald Vogels, Robert H.E. Friesen, Philippe Alard, Stefan Loverix, Katarina Radosevic
-
Publication number: 20160355553Abstract: The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein on or more amino acids in the HA2 domain have been mutated. Also provided are nucleic acids encoding the polypeptides, compositions comprising the polypeptides and/or nucleic acid molecules, as well as methods of their use, in particular in the detection, prevention and/or treatment of influenza.Type: ApplicationFiled: August 22, 2016Publication date: December 8, 2016Applicant: Janssen Vaccines & Prevention B.V.Inventors: Jan Willem Meijberg, Antonietta Impagliazzo, Ronald Vogels, Robert H.E. Friesen, Philippe Alard, Stefan Loverix, Katarina Radosevic
-
Patent number: 9452211Abstract: The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein on or more amino acids in the HA2 domain have been mutated. Also provided are nucleic acids encoding the polypeptides, compositions comprising the polypeptides and/or nucleic acid molecules, as well as methods of their use, in particular in the detection, prevention and/or treatment of influenza.Type: GrantFiled: November 27, 2012Date of Patent: September 27, 2016Assignee: Janssen Vaccines & Prevention B.V.Inventors: Jan Willem Meijberg, Antonietta Impagliazzo, Ronald Vogels, Robert H. E. Friesen, Philippe Alard, Stefan Loverix, Katarina Radosevic
-
Publication number: 20160039867Abstract: The present invention relates to single-chain proteins of the formula HRS1-L1-HRS2-L2-HRS3, wherein HRS1, HRS2 and HRS3 are heptad repeat sequences and L1 and L2 are structurally flexible linker sequences, and wherein HRS1, HRS2 and HRS3 form a thermodynamically stable triple-stranded, antiparallel, alpha-helical coiled coil structure in aqueous solution. The invention also relates to amino acid sequence variants, conditions and methods to obtain such proteins and variants, and usages thereof, especially their usage as scaffolds and as therapeutic products.Type: ApplicationFiled: August 21, 2015Publication date: February 11, 2016Applicant: Complix NVInventors: Johan Desmet, Ignace Joseph Isabella Lasters, Stefan Loverix
-
Publication number: 20150376282Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.Type: ApplicationFiled: June 15, 2015Publication date: December 31, 2015Inventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jan Van De Winkel, Janine Schuurman, Ignace Laster
-
Publication number: 20150368345Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of lgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.Type: ApplicationFiled: June 15, 2015Publication date: December 24, 2015Inventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jan Van De Winkel, Janine Schuurman, Ignace Laster
-
Publication number: 20150266968Abstract: Provided herein are polypeptides that are capable of crossing the cellular membrane and entering into the intracellular environment, which polypeptides are suitable for use in prophylactic, therapeutic or diagnostic applications as well as in screening and detection. Nucleic acids encoding such polypeptides; methods for preparing such polypeptides, host cells expressing or capable of expressing such polypeptides, compositions, and in particular pharmaceutical compositions, that comprise such polypeptides, in particular for prophylactic, therapeutic or diagnostic purposes are also provided.Type: ApplicationFiled: October 22, 2013Publication date: September 24, 2015Inventors: Stefan Loverix, Philippe Alard, Sabrina Deroo, Klaartje Somers, Ignace Lasters, Johan Desmet
-
Publication number: 20150266925Abstract: The application provides Alphabodies that specifically bind to IL-23, as well as to polypeptides that comprise or essentially consist of such Alphabodies. Also provided herein are nucleic acids encoding such Alphabodies; to methods for preparing such Alphabodies and polypeptides; and in particular to pharmaceutical compositions, that comprise such Alphabodies, polypeptides, nucleicacids and/or host cells.Type: ApplicationFiled: October 22, 2013Publication date: September 24, 2015Applicant: COMPLIX NVInventors: Johan Desmet, Maria Paulina Henderikx, Klaartje Somers, Stefan Loverix, Mark Vaeck, Ignace Lasters
-
Patent number: 9085625Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.Type: GrantFiled: December 3, 2009Date of Patent: July 21, 2015Assignee: Genmab A/SInventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jau Van De Winkel, Janine Schuurman, Lgnace Laster
-
Publication number: 20140363434Abstract: The application provides polypeptides comprising or essentially consisting of at least one Alphabody, wherein said Alphabody is capable of internalization into a cell and specifically binds to an intracellular target molecule. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells; and uses of such polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: January 4, 2013Publication date: December 11, 2014Applicant: COMPLIX NVInventors: Ignace Lasters, Mark Vaeck, Johan Desmet, Jürgen Debaveye, Sabrina Deroo, Stefan Loverix
-
Publication number: 20140357845Abstract: The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein on or more amino acids in the HA2 domain have been mutated. Also provided are nucleic acids encoding the polypeptides, compositions comprising the polypeptides and/or nucleic acid molecules, as well as methods of their use, in particular in the detection, prevention and/or treatment of influenza.Type: ApplicationFiled: November 27, 2012Publication date: December 4, 2014Inventors: Jan Willem Meijberg, Atonietta Impagliazzo, Ronald Vogels, Robert H.E. Friesen, Philippe Alard, Stefan Loverix, Katarina Radosevic
-
Publication number: 20120020952Abstract: The invention relates to a method for producing a mixture comprising two or more different antibodies in a single recombinant host cell. In one embodiment, a mixture of different monovalent antibodies is produced. In another embodiment, a mixture of monovalent and bivalent antibodies is produced. The invention also relates to mixtures of antibodies obtainable by the method of the invention and to light chain sequences that are particularly useful in the method of the invention.Type: ApplicationFiled: January 26, 2010Publication date: January 26, 2012Applicant: GENMAB A/SInventors: Paul Parren, Joost J. Neijssen, Aran Frank Labrijn, Janine Schuurman, Tom Vink, Jan Van De Winkel, Stefan Loverix, Ignace Lasters
-
Publication number: 20110294983Abstract: The present invention relates to single-chain proteins of the formula HRS1-L1-HRS2-L2-HRS3, wherein HRS1, HRS2 and HRS3 are heptad repeat sequences and L1 and L2 are structurally flexible linker sequences, and wherein HRS1, HRS2 and HRS3 form a thermodynamically stable triple-stranded, antiparallel, alpha-helical coiled coil structure in aqueous solution. The invention also relates to amino acid sequence variants, conditions and methods to obtain such proteins and variants, and us ages thereof, especially their usage as scaffolds and as therapeutic products.Type: ApplicationFiled: December 8, 2009Publication date: December 1, 2011Applicant: Complix NVInventors: Johan Desmet, Ignace Joseph Isabella Lasters, Stefan Loverix
-
Publication number: 20110293607Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.Type: ApplicationFiled: December 3, 2009Publication date: December 1, 2011Inventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jau Van De Winkel, Janine Schuurman, Lgnace Laster